Pacific Bio (PACB) Q3 Revenue Misses Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Bio (NASDAQ: PACB) reported Q3 EPS of $0.02, may not compare to the analyst estimate of ($0.27). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $15.84 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Wells Fargo starts On Holding at Overweight, sees growth reaccelerating in 2027
- Alphabet stock jumps as buyers return after selloff
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
